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Abstract
Aldolase A deficiency has been reported as a rare cause of hemolytic anemia occasionally associated with myopathy. We
identified a deleterious homozygous mutation in the ALDOA gene in 3 siblings with episodic rhabdomyolysis without
hemolytic anemia. Myoglobinuria was always triggered by febrile illnesses. We show that the underlying mechanism
involves an exacerbation of aldolase A deficiency at high temperatures that affected myoblasts but not erythrocytes. The
aldolase A deficiency was rescued by arginine supplementation in vitro but not by glycerol, betaine or benzylhydantoin,
three other known chaperones, suggesting that arginine-mediated rescue operated by a mechanism other than protein
chaperoning. Lipid droplets accumulated in patient myoblasts relative to control and this was increased by cytokines, and
reduced by dexamethasone. Our results expand the clinical spectrum of aldolase A deficiency to isolated temperature-
dependent rhabdomyolysis, and suggest that thermolability may be tissue specific. We also propose a treatment for this
severe disease.
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Introduction
Massive rhabdomyolysis is a life threatening condition and has
been associated with mitochondrial fatty acid ß-oxidation defects
(FAO) [1–3], LPIN1 mutations [4–6], as well as, rarely, with
mitochondrial respiratory chain (RC) deficiency, dystrophinopa-
thies and inborn errors of glycogenolysis and glycolysis [3,7].
Among inherited defects of glycolysis, isolated rhabdomyolysis is not
an usual presentation. Because most metabolic mechanisms of
rhabdomyolysis are triggered by fever, differential diagnoses include
myositis and viral infections for non recurrent cases. Metabolic
work-up focuses on plasma carnitine and acylcarnitine profiles,
urinary organic acids analysis, then sequencing of LPIN1 gene in
young children. In older children, ischemic stress test can orient
toward anaerobic glycolysis defects. In both young and older
patients, skeletal muscle biopsy may be proposed for histological
studies in cases of negative biochemical and molecular results. In
spite of this wide range of investigations, the disease mechanism
remains unknown in at least half of the recurrent cases [8].
In order to identify new etiologies of recurrent rhabdomyolysis
in young children, we used exome sequencing in siblings suffering
from severe episodes of rhabdomyolysis triggered by fever since
age 2 months. This led us to identify a new phenotype of ALDOA
mutations. The absence of hemolytic anemia was explained by
tissue specific expression of protein thermolability. The occurrence
of thermolability supports the contention that viral infections
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should remain a diagnosis of exclusion for rhabdomyolysis. Our
results raise the possibility of medical therapy by arginine.
Results
Case report
Three patients from a Moroccan consanguineous family
(Figure 1A) suffered from recurrent episodes of rhabdomyolysis
that required numerous hospitalizations from 2 months of age.
These acute episodes were invariably triggered by febrile illnesses.
The presenting symptoms were an inability to walk and myalgia.
During the acute episodes, plasma creatine phosphokinase (CK)
levels were variable, ranging from markedly elevated (peak levels:
180,000–450,000 U/L, N,150) with overt myoglobinuria to
milder elevations (3,000 U/L). The following tests were normal:
hemoglobin, hematocrit, mean corpuscular volume, platelet-
count, reticulocyte count, bilirubin, haptoglobin, ferritin,
Coombs’ test, urea, creatinine, blood gasses, plasma lactate,
carnitine, blood acylcarnitine profile, plasma amino acids, and
urinary organic acids. Electromyography, brain MRI, abdominal
ultrasonography, and echocardiography were also normal. CK
levels ranged from normal (,150 U/L) to elevated (up to
1,800 U/L) in all 3 patients between acute episodes. The clinical
examination and muscle tests performed 2 months after an
episode of rhabdomyolysis were normal for each patient, at ages
9, 10, and 11 years respectively. Family history revealed neither
chronic hemolytic anemia, nor episodes of jaundice or blood
transfusions. Two patients suffered from learning disabilities and
required a special school.
Molecular studies
Exome sequencing analysis pointed to 10 candidate genes
harboring homozygous mutations (Table S1). The ALDOA gene
was considered because all 3 affected patients harbored the
homozygous mutation c.839 C.T (p.Ala279Val, NM_000034),
whereas the healthy sibling and the parents were heterozygous.
This gene was located in a homozygous region revealed by
homozygosity mapping, between the polymorphic markers
D16S3022 and D16S323. Polyphen software predicted that this
change, located in a sequence conserved between species (Figure
S1), was ‘‘probably damaging’’. The homozygous mutation p.
Ala279Val was localized near the previously described Cys338re-
sidue involved in a hematological and muscle phenotype[9] close
to a ‘‘hinge’’ region that is critical for a conformational change in
the C-terminus (Figure 1B). Prediction from seven combined
softwares as implemented in iSTABLE [10] was consistent with
A279V destabilizing the protein. Therefore, this mutation is likely
involved in maintaining the correct spatial conformation of the
enzyme (see below) [9,11].
Morphological studies
All histological and cellular experiments were performed with
the tissue and myoblasts from the same patient aged 10 (Patient 3,
Figure 1C).
Microscopy showed an excessive lipid droplet (LD) accumula-
tion, visualized with oil-red-O staining (Figure 2A), in the muscle
biopsy from the patient (a) compared with control biopsies (b).
However, the muscle tissue of the patient showed a well-preserved
fascicular architecture with normal type 1 and type 2 fibers. In
addition, the cytochrome c-oxidase and phosphorylase staining
patterns were similar to controls.
Representative cultures of the patient under basal (a) or pro-
inflammatory conditions (b) are shown in Figure 2B. Oil-red-O
staining of the neutral lipids revealed massive accumulation of LDs
after 24 hours of TNFa+IL-1ß stimulation (b), whereas no change
in the size or the number of the LDs was observed at 40uC (Figure
S2). In contrast, control myoblasts exhibited no LDs under basal
condition and a moderate accumulation after TNFa+IL-1ß
stimulation (Figure S3). Co-treatment with anti-inflammatory
agents and particularly treatment with the synthetic glucocorticoid
dexamethasone combined with TNFa+IL-1ß (c) or alone (d),
dramatically decreased the number of LDs in patient myoblasts.
The effect of the ALDOA knockdown on LD accumulation was
investigated in order to test if muscle abnormalities seen in patients
result from ALDOA decrease. Transfection with a siRNA that
knocked down ALDOA expression (as confirmed by RT-PCR,
Figure 2C), induced a 48% increase in the number of LDs in the
control myoblasts (Figure 2Da,b) and a 5.5% increase in the
patient cells (Figure 2Dc,d).
Biochemical studies
ALDOA activity was dramatically decreased in patient eryth-
rocytes (0.4 to 0.6 U/g Hb; control 4.6) (Figure 1C) and frozen
skeletal muscle (55 nmol/h/mg; normal 581-5188) though to a
lesser degree in myoblasts (1.0860.4 U/mg protein; normal
2.460.025). Activity was approximately half the normal in the
heterozygote (Figure 1C), supporting the pathogenic nature of the
c.839 C.T mutation and the recessive inheritance of the disease.
Studies of muscle anaerobic glycogenolysis and glycolysis in vitro
revealed reduced lactate production, consistent with dysfunctional
glycolysis (Figure 1D). The glucose-6-phosphate dehydrogenase
and hexokinase activities were normal or elevated in all affected
patients’ erythrocytes (Figure 1C). Carbons from stable isotope
labeled glutamine were incorporated to a lesser degree into Krebs
cycle intermediates in the patient myoblasts relative to controls,
consistent with ALDOA deficiency leading to decreased glycolytic
flux (Figure S4).
We studied whether temperature or pro-inflammatory cytokines
affected ALDOA expression. To this end, the patient and the
control myoblasts were cultured at 37 or 40uC, under basal
conditions or with the combination of TNFa+IL-1b. Myoblasts
from the patient and the controls responded to pro-inflammatory
stress by significant secretion of IL6, peaking at approximately
24 hours of TNFa+IL-1ß stimulation (20-fold). The level of
ALDOA mRNA was unchanged in patient myoblasts after
exposure to TNFa+IL-1b or 40uC (Figure 3A upper panel),
whereas the corresponding protein level was reduced in patient
myoblasts in basal conditions (0.660.09; control: 1.360.17) and
was further abated at 40uC (barely detectable) compared to control
(0.860.16) (Figure 3A, lower panel). In contrast, TNFa+IL-1b
treatment did not affect the protein level (1.260.11 to 0.9760.11
in control and 0.760.09 to 0.860.13 in patient myoblasts).
Accordingly, aldolase activity in the patient myoblasts dramatically
decreased after incubation from 25uC, 37uC through 40uC
Abstract Summary
Using recent technical advances involving exome analysis,
we identified a new missense mutation in the ALDOA gene,
encoding a key enzyme in the glycolytic pathway. The
patients presented with severe recurrent rhabdomyolysis
without hemolytic anemia. The decrease of aldolase A
activity in myoblasts was enhanced at high temperature
and could explain the fever-induced rhabdomyolysis. By
contrast, enzyme thermolability was not found in erythro-
cytes, possibly accounting for the unusual clinical pheno-
type of the patients. Enzyme thermolability was rescued by
arginine supplementation in vitro but not by other
chaperone compounds.
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(residual activity 10% and 5% respectively), and to a lesser degree
in the control myoblasts (residual activity 61% at 37uC and 43% at
40uC) (Figure 3B). TNFa+IL-1b treatment did not change the
level of activity in the patient or the control myoblasts (Figure 3B).
Interestingly, aldolase A activity in erythrocytes from the three
patients was not modified by high temperature (Figure 3C). These
results suggest that the mutant enzyme might be differentially
destabilized in distinct tissues, i.e., only in myoblasts and not in
erythrocytes.
Arginine supplementation significantly enhanced aldolase A
activity in patient myoblasts compared to untreated cells
(Figure 3D, upper panel); this effect may be explained by an
increase of the protein level (Figure 3D, lower panel). By contrast,
glycerol, benzylhydantoin and betaine did not modify aldolase
activity and protein (Table S2), suggesting that arginine-mediated
rescue did not operate as a protein chaperone. Arginine did not
contribute carbons to Krebs cycle intermediates in 6-hr stable
isotope labeling experiments in myoblasts (Figure S4), thus
indicating that arginine did not represent a major source of
compensatory fuel for energy production.
The respiratory chain activities were increased in the frozen
skeletal muscle compared to control and similar in the myoblasts
of the patient and the control (Table S3). Similarly, fatty acid
oxidation (FAO) results were normal in patient myoblasts
compared to control and were not affected by pro-inflammatory
conditions (Table S4).
Discussion
Massive rhabdomyolysis is a life-threatening situation, yet a
molecular mechanism is found in only half of the recurrent cases.
Because glycolysis is the most important source of energy in
erythrocytes and in some types of skeletal muscle fibers, inherited
defects of glycolysis can cause hemolytic anemia or the combina-
tion of hemolytic anemia, neurologic abnormalities, and myopathy
[12]. By exome sequencing and homozygosity mapping, we
identified a new phenotype associated with aldolase A deficiency.
The phenotype affects skeletal muscle with no hemolytic
symptoms, while mild learning disabilities were identified in 2 of
the 3 siblings.
Only 5 patients with aldolase A deficiency have been reported
so far (Table 1) [9,13–16]. All presented with non-spherocytic
hemolytic anemia (OMIM #103850), a few had mental retarda-
tion [13,15] and 2 also displayed rhabdomyolysis leading to death
[9,13]. Because of the involvement of ALDOA in skeletal tissue
function and the observation of muscle symptoms in 2 previous
cases with hemolytic anemia, we inferred that ALDOA mutations
could be responsible for rhabdomyolysis in our family. In
Figure 1. 1A: Family tree showing the 3 affected children. 1B: Crystal structure of human muscle aldolase complexed with fructose 1,6-
bisphosphate (isoenzyme A, PDB code 4ALD) superimposed with the tetrameric crystal structure of human brain aldolase (isoenzyme C, PDB code
1XFB), which is similar to the muscle isoenzyme. Chains A, B, C and D of isoenzyme C are shown in orange, light blue, light green and pink,
respectively. Monomeric isoenzyme A is shown in grey and is superimposed on chain D of the tetrameric isoenzyme C. Fructose 1,6-bisphosphate co-
crystallized with isoenzyme A is shown in yellow. The mutated residue described in this report (red arrow) and the mutated amino acids previously
described are highlighted in the magnified structure. The structural and functional consequences of the mutations are described in Table 1. 1C:
aldolase A, glucose-6-phosphate dehydrogenase (G6PD) and hexokinase activities in the erythrocytes of the parents, the healthy sibling and the 3
affected patients (*: patients 2, 3, 4). 1D: in vitro muscle study of anaerobic glycogenolysis and glycolysis (only patient 3); results of lactate production
(mmol/g muscle in 30 minutes) after incubation with various substrates.
doi:10.1371/journal.pgen.1004711.g001
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agreement with this, we showed the effect of the ALDOA
knockdown on LD accumulation in patient myoblasts, and that
they were enhanced by ALDOA siRNA in non-inflammatory
conditions compared to control. LD accumulation was further
enhanced in inflammatory conditions, consistent with the fact that
intracellular accumulation of lipids is a common feature of
proinflammatory stress [17,18]. LD are dynamic organelles and
provide key storage compartments that participate in the response
to increased energetic demand [19] and in the regulation of
cellular lipid metabolism, thus being involved in the delicate
balance between triacylglycerol deposition and mobilization. LD
accumulation as frequently observed in energetic diseases could
result from a metabolic adaptation of the affected cells.
We were puzzled to find no evidence of hemolytic anemia in
our patients although residual enzyme activity was 9% in
erythrocytes and 45% in skeletal myoblasts. This may be related
to the greater residual enzyme activity observed in our patients
(approximately 10%) compared to previously reported cases of
ALDOA deficiency (approximately 5%). Also, the hematological
investigation was performed outside of an acute episode of
decompensation. Of note, alternative explanations cannot be
ruled out, including variable expressivity (degree of metabolic
stress) or a selective resistance to thermolability in erythrocytes (cell
type specific protein-protein interactions).
Because aldolase A is physiologically active as an homotetramer,
the integrity of the quaternary structure was suggested to confer
thermal stability to the enzyme [20] and was found to be
vulnerable in erythrocytes [11,16] as well as according to
iSTABLE prediction [10]. However, thermolability of aldolase A
was found only in patient myoblasts, not in erythrocytes, and it
was observed at lower temperature than previously described
[11,13,14,16]. Red blood cells contribute to about 40% of the
blood volume and are the first cellular structures to respond to
increased reactive oxygen species (ROS) activity [21]. Because
they do not have nucleus, they rely on pre-existing proteins for
protection against ROS damage [22] and possess an extensive
array of antioxidants [23]. Also, they develop a system of defenses
that represent an excellent example of redox balance maintenance
[24]. Interestingly, we showed that protein and catalytic break-
down can be reversed by arginine but not by glycerol,
benzylhydantoin and betaine which all might act as a chaperone
as recently proposed for unrelated metabolic disorders [25–27].
Also, another mechanism may be proposed concerning the
effective role of L-arginine on aldolase A activity, namely its
antioxidant function via increased NO formation and reduced
release of superoxide.
Wen et al. [28] described the role of the inflammasome complex
and IL-1b [29] in the Warburg effect of aerobic glycolysis, which
was recently shown to be promoted by lipopolysaccharides. [30]
Conversely, glucose metabolism plays a crucial role in IL-1b
transcription because high glucose boosts the production of IL-1 b
in pancreatic beta cells. [31] However, myoblasts from the patient
did not exhibit altered or abnormal IL-1b secretion. Moreover, the
levels of most cytokines measured (see above) were undetectable or
very low in patients’ plasma. Similar results were obtained for
healthy donors.
Figure 2. Oil-red-O staining of skeletal muscle and myoblasts from our patient and a control. Images were taken with x20 magnification.
2A: Transverse cross-section of a left deltoid muscle biopsy of the patient shows the presence of numerous LDs, mainly in type 1 fibers, a: control, b:
patient. 2B: Cytological oil-Red-O analysis of the patient myoblasts cultivated under basal (a) or pro-inflammatory conditions (TNFa+IL-1b) (b). LDs
appear as red circular vacuoles in the cytoplasm. Treatment with dexamethasone alone (d) or combined with TNFa+IL-1b (c) reversed the LD
phenotype. 2C: Relative knockdown of aldolase A expression in control and patient myoblasts. 2D: representative oil-red-O staining of mock-
transfected control (a) and patient (c) cells, or aldolase A-siRNA-transfected control (b)and patient (d) myoblasts.
doi:10.1371/journal.pgen.1004711.g002
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Due to LD accumulation in our patient muscle cells, consistent
with findings in a previous patient [13], and because adenosine
triphosphate (ATP) has several origins, we also examined FAO
metabolism and OXPHOS. Moreover, pro-inflammatory cyto-
kines are known to down regulate lipid metabolism. [32]
However, FAO and OXPHOS metabolism were normal
compared to control myoblasts, and no change in patient
myoblasts was observed after TNFa+IL-1b treatment. LD
accumulation may result from anaplerotic dysfunction of the
Krebs cycle. [33] Consistent with this possibility, we found
reduced incorporation of carbon from stable isotope labeled
glutamine (Figure S4). A number of secondary events may also
play a role in muscle pain such as lipotoxicity [34] and osmotic
and ionic modifications with consequences for ionic exchange.
[35] The role of ALDOA as a scaffold protein that coordinates
actin and microtubule networks can also be speculated to
participate in the biogenesis of lipid droplet. [36,37] [38]
Aldolase A has been shown to bind to vacuolar-type H+-ATPase
(V-ATPase) with ARNO (an ADP-ribosylation factor guanine
nucleotide exchange factor). [39] Interestingly, ARNO has been
recently found to restore/promote lipid droplet formation. [40]
Therefore, attractive mechanisms may stem from putative
aldolase-ARNO interacting properties.
In conclusion, aldolase A deficiency is a rare cause of severe
myoglobinuria in early childhood, as a consequence of impaired
generation of ATP to fuel muscle metabolism. Our study points to
the crucial role of fever as the trigger of rhabdomyolysis in our
patients. High temperature and a combination of pro-inflamma-
tory cytokines, utilized to mimic inflammatory conditions, led to
decreased aldolase A activity and LD accumulation, respectively,
in both the patient myoblasts and to a lesser extent, in the control
myoblasts.
Thermolability selectively found in myoblasts and not in
erythrocytes of the patients plays a crucial role in the
pathophysiology of this disease. Finally, we showed that
arginine may be a useful therapy that enhances the enzymatic
activity in patient cells, probably more by another role, i.e. its
antioxidant effect than by a chaperone role, whereas inflam-
matory conditions enhanced LD accumulation and, therefore,
lipotoxicity.
Figure 3. ALDOA expression and activity. 3A:ALDOA mRNA expression in control myoblasts (C, white bars) and the patient myoblasts (P, grey
bars) under basal conditions, with TNFa+Ilb treatment (left) or at a high temperature (right, 40uC); Aldolase A protein levels (lower panel) under basal
conditions, with TNFa+Ilb treatment or at a high temperature. 3B: Aldolase A activity in control and the patients’ myoblasts under the same
conditions: basal conditions, TNFa+Ilb treatment and at different temperatures. The results are shown as the mean value 6SD from 3 independent
experiments. 3C: Aldolase A activity in control and patients erythrocytes under basal conditions and at different temperatures. The results are shown
as the mean value of two independent experiments. 3D: Aldolase A activity (upper) and protein level (below) in the patient myoblasts under basal
condition and after arginine (Arg) treatment.*: p,0,05).
doi:10.1371/journal.pgen.1004711.g003
ALDOA and Temperature-Dependent Rhabdomyolysis
PLOS Genetics | www.plosgenetics.org 5 November 2014 | Volume 10 | Issue 11 | e1004711
Materials and Methods
Molecular studies
To identify the causative mutations for rhabdomyolysis in this
family, exome sequencing was performed in 1 child using
previously described methods. [41] All variants were annotated
using an in-house-developed annotation software system. The
variants were classified as previously unidentified when they were
absent from the control populations and from all datasets,
including dbSNP129, the 1000 Genomes Project, and in-house
exome data.
The coding regions and flanking splice sites of the ALDOA
(NM_000034) gene were sequenced using genomic DNA prepared
from leukocytes.
Real-time quantitative PCR (RT-qPCR) assays were performed
using cDNAs from myoblasts. All experiments were conducted in
triplicate using an ABI PRISM 7300 Sequence Detection System
instrument with SYBR Green fluorescence dye (Applied Biosys-
tems).
The protein concentrations in myoblasts were determined using
the Bradford method (Sigma).Forty micrograms of protein were
separated using denaturing PAGE and transferred to PVDF
membranes. After probing with the suitable antibodies (ALDOA
(sc-12059, Santa Cruz), a-tubulin (T9026, Sigma) or b2actin (sc-
81178, Santa Cruz)), the signals were detected using the ECL kit
(GE Healthcare).
Swiss-Pdb Viewer 3.7 (http://www.expasy.org/spdbv) was used
to analyze the crystal structure of the human muscle fructose 1,6-
bisphosphate aldolase complex (PDB code 4ALD). Prediction of
protein stability changes was obtained from seven combined
softwares as implemented in iSTABLE [10].
The ethics committee of the Necker Hospital approved the
research proposal. Informed consent was obtained from the
siblings’ parents.
Morphologic and biochemical studies
Histological studies were performed on a skeletal muscle biopsy
and myoblasts obtained from Patient3 left deltoid muscle
(Figure 1A) as previously described. [42] Samples from 2age-
and sex-matched controls were obtained. Myoblasts were subject-
ed to various stress conditions mimicking those believed to trigger
the episodes of rhabdomyolysis, including high temperature (40uC)
[13] and pro-inflammatory cytokines TNFa+IL-1ß(10 ng/mlfor
24 hours; all from R&D Systems). [43]To evaluate the response of
myoblasts to these stimuli,IL6/IL8 release into the culture
medium was measured using an immunoradiometric assay kit
(Immunotopics). [44] An inflammatory cytokine kit was used to
determine the contents of 10 cytokines (BD, Bioscience) in blood
plasma. The cytokine inhibitors anakinra (inhibitor of the IL-1b
receptor, 1 mg/mL) and ab9635 (inhibitor of TNFa, 1 mg/mL), or
the synthetic glucocorticoid dexamethasone (0.2 mM) were added
to the culture medium 1 hour or 12 hours, respectively, prior to
the 24 hour-incubation with TNFa+IL-1b.
The enzymatic activities in erythrocytes and myoblasts were
determined according to the methods of the International
Committee for Standardization in Hematology. [45] To study
the effect of temperature, myoblast extracts and erythrocytes were
incubated for 30 minutes at 4uC, 25uC, 37uC, 39uC,or 40uC
before enzyme assay. In the presence of suitable cofactors
(including ATP and NAD+) and substrates for multiple enzymes
involved in glycolysis (Figure1D), we measured L-lactate formation
after incubation of frozen homogenized muscle tissue at 37uC for
30 min under nitrogen gas according to a published protocol. [46]
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Mitochondrial OXPHOS activities of the myoblasts were
evaluated as previously described. [47] Fatty-acid oxidation
(FAO) measurements were performed through the assay of
deuterated C2 to C16 acylcarnitines generated by incubation of
intact myoblasts with a pentadeuterated C16 fatty acid ([16-2H3,
15-2H2]-palmitate) according to a procedure used for the detection
of b-oxidation defects. [48]
RNA-silencing (siRNA) experiments were performed on myo-
blasts using the jePRIME transfection reagent (Polyplus) according
to the supplier’s recommendations and 25 nM of siRNA targeting
human AldoA(M-010375,Dharmacon). The non-targeting siRNA
#2 (Dharmacon) was used as a negative control.
The effect of arginine supplementation was investigated in
patients’ myoblasts incubated with 2 mM of L-arginine hydro-
chloride (Sigma) for 10 days. Three other chaperons (sigma) were
also tested, glycerol (100 mM) [25] for 10 days, betaine (10 and
50 mM) [26,27] and benzylhydantoin (130 mM) for 3 days.
Uniformly stable isotope labeled (U-13C5) glutamine or (U-
13C6)
arginine (Eurisotop, Saint-Aubin, France) were provided to
myoblasts (1 mM) in the presence of glucose (2.5 mM) and
incubated without serum for 6 hours. Krebs cycle intermediates
and their isotopomers were measured by gas chromatography
mass spectrometry (Scion TQ, Bru¨ker) using standard derivation
by BSTFA [N,O-Bis(trimethylsilyl)trifluoroacetamide] and 1%
trimethylchlorosilane.
Supporting Information
Figure S1 Aldolase A amino acid sequence alignment. The
partial AldoA patient’s sequence was aligned to orthologs from
mouse (P05064), rabbit (P00883), zebra-fish (AAN04476.1).
Human Aldolase A (P04075).
(TIFF)
Figure S2 Oil-red-O staining of myoblasts from our patient. No
change in the size or the number of the LDs was observed in
patient myoblasts at 40uC.
(TIFF)
Figure S3 Oil-red-O staining of myoblasts from a control.
Control myoblasts exhibited no LDs under basal condition and a
moderate accumulation after TNFa+IL-1ß stimulation.
(TIFF)
Figure S4 Stable isotope labeling experiments showing reduced
ratios of labeled to natural isotope Krebs cycle intermediates
(citrate, succinate, fumarate and malate) in patient myoblasts
treated with uniformly labeled 1 mM glutamine (GLN*) relative
controls, thus consistent with partial dysfunction of central energy
metabolism in ALDOA deficient fibroblasts. No incorporation of
arginine (ARG*) was observed in either patient or control
myoblasts, indicating no major contribution of arginine to energy
production. Bottom right: schematic of ‘‘central metabolism’’ as
discussed in the text related to glutamine and arginine. Dotted
lines indicate that one or more enzymatic steps are omitted for the
sake of simplicity’’.
(TIFF)
Table S1 Candidate genes with exome analysis.
(PDF)
Table S2 Aldolase A activity in patient myoblasts treated with
glycerol, betaine and benzylhydantoin.
(PDF)
Table S3 Increased respiratory chain activities in skeletal muscle
of the patient and similar respiratory chain activities in myoblasts
of the patient and control, in basal condition and in pro-
inflammatory conditions (T+I). T: TNF-a; I: IL-1b.
(PDF)
Table S4 Normal fatty acid oxidation in patient myoblasts
compared to control, in basal and pro-inflammatory conditions
(TNF-a + IL-1b).
(PDF)
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